Small nucleic acid CXO, serving as the core support for the small nucleic acid drug industry, is benefiting from technological breakthroughs and accelerated commercialization, leading to a continuous rise in the sector's prosperity. The small nucleic acid CXO industry has simultaneously entered a rapid development track, forming a comprehensive CRDMO service chain that integrates "R&D services - pilot-scale amplification - commercial production." Focus is placed on two types of CXO companies actively involved in the small nucleic acid field: CRO companies possessing core technologies such as chemical modification, delivery systems, and conjugation technologies, along with extensive experience in small nucleic acid projects; and CDMO companies that have made forward-looking investments and possess leading production capabilities. The report states that small nucleic acid drugs are currently experiencing a period of vigorous global development, transitioning from the technology validation phase into a stage of clinical validation and accelerated commercialization. Globally, from 2019 to 2023, the market size for small nucleic acids grew from $2.7 billion to $4.6 billion, representing a compound annual growth rate of 14.25%; it is projected that the market size will climb to $45.7 billion by 2033, with a CAGR as high as 26.08%. A cumulative total of 23 small nucleic acid drugs have received approval for marketing worldwide, covering various technological approaches such as siRNA, ASO, and aptamers. Although no products have been launched domestically in China yet, the number of R&D pipelines ranks second only to the United States, spanning numerous therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney disease, muscular diseases, and obesity. Notable out-licensing deals have emerged, such as the cumulative collaboration between BOWANG Pharmaceutical and Novartis exceeding $9 billion, and the platform authorization deal between RIBO Biological and Boehringer Ingelheim worth $2 billion. Traditional pharmaceutical companies like Sino Biopharmaceutical are also rapidly securing their positions through acquisitions, indicating a positively developing industry landscape.